


Product Name : Rezivertinib
Cat. No. : PC-38343
CAS No. : 1835667-12-3
Molecular Formula : C₂₇H₃₀N₆O₃
Molecular Weight : 486.576
Target : EGFR
Solubility : 10 mM in DMSO



Biological Activity

Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M mutations, shows potential against T790M-mediated drug resistance.

Rezivertinib (BPI-7711) specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells.

Rezivertinib (BPI-7711) shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR.

References

Yuankai Shi, et al. J Thorac Oncol. 2022 Feb 15;S1556-0864(22)00084-3.

Nagasaka M, et al. J Thorac Oncol. 2021 May;16(5):740-763.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com